A professor who refused to bow to activist progressives and parrot land acknowledgements has scored a major First Amendment legal victory — after a years-long battle. “I’m not going to be silenced.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Hiring or promotion practices that “prioritizes candidates from underrepresented groups” for admission, hiring, promotion, bypassing qualified candidates who do not belong to those groups. Creating a ...

Rachel Ho is a rising 10th-grader at Langley High School in McLean. She loves writing and thinks she might want to follow in her mother’s footsteps and study at the University of Virginia. To get a ...

Lucy Spence is an intern for The Daily Signal. FIRST ON THE DAILY SIGNAL—Indiana is forging ahead in its efforts to dump diversity, equity, and inclusion programs in state government. Indiana Gov.

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...